Health Condition 1: null- Type 2 Diabetes mellitus prediabetes
Conditions
Interventions
Intervention1: Canagliflozin: Canagliflozin 100mg once daily orally will be given in both groups of type 2 diabetes patients (both with glucose levels between 180-250 mg/dl). Group 1: with Glycosuria
Sponsors
Research Society for the Study of Diabetes in India
Eligibility
Inclusion criteria
Inclusion criteria: Healthy subjects- normoglycaemic (Fasting glucose Individuals with prediabetes: (Fasting glucose 140 mg/dl but
Exclusion criteria
Exclusion criteria: • Prior SGLT2 inhibitor therapy in last 6 months • Individuals on insulin therapy • Contraindications to SGLT2 inhibitor therapy • Comorbidities requiring hospital admission including CVA, CAD, CKD, dialysis, surgery, pregnancy, lactation, or complications arising thereof.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| This study will be first of its kind to help us to define If SGLT2/GLUT2 is overexpressed in Indians with Type 2 Diabetes and/or individuals with pre-diabetes. This will provide pathophysiological basis for prediction of treatment benefit with SGLT2 inhibitors in Indians. This study is likely to provide clinical insights into patient characteristics which help predict response to SGLT2 inhibitors (example presence or absence of glycosuria. Timepoint: 1year | — |
Secondary
| Measure | Time frame |
|---|---|
| This will provide pathophysiological basis for prediction of treatment benefit with SGLT2 inhibitors in Indians. This study is likely to provide clinical insights into patient characteristics which help predict response to SGLT2 inhibitors (example presence or absence of glycosuria. Timepoint: 1year | — |
Countries
India
Contacts
Public ContactDr Sujoy Ghosh
INSTITUTE OF POSTGRADUATE MEDICAL EDUCATION AND RESEARCH AND SSKM HOSPITAL
Outcome results
None listed